Epstein Barr Virus VCA IgM, 96 Wells
To add this product to your interest list, sign up or login.
Manufacturer: DRG International Inc.
Model: Epstein Barr Virus VCA IgM, 96 wells
Product Code: EIA2794
The Epstein Barr Virus VCA IgM, 96 wells is one among many essential infectious disease kits available at Block Scientific. We have a wide range of laboratory supplies and equipment from popular manufacturers in the industry. We are one of the leading laboratory equipment dealers in Bellport, New York.
Epstein Barr Virus ELISA
– Useful and Reliable
The DRG International, Inc. EBV-VCA IgM ELISA test system is an enzyme-linked immunosorbent assay ELISA) designed for the qualitative detection of IgM class antibodies to Epstein-Barr Virus viral capsid antigen (EBV-VCA) in human serum. The test system is intended to be used for the diagnosis of EBV-associated infectious mononucleosis when used in conjunction with other EBV serologies.
Epstein-Barr Virus (EBV) is a ubiquitous human virus which causes infectious mononucleosis (IM), a self limiting lymphoproliferative disease (1). By adulthood virtually everyone has been infected and has developed immunity to the virus. In underdeveloped countries, seroconversion to the virus takes place in early childhood and is usually asymptomatic (2). In more affluent countries, primary EBV infections are often delayed until adolescence or later, and manifest as IM in about 50% of this age group (3-5). Following seroconversion, whether symptomatic or not, EBV establishes a chronic, latent infection in B lymphocytes which probably lasts for life (6). EBV replicates in oropharyngeal epithelial cells and is present in the saliva of most patients with IM (7). Also, 10-20% of healthy persons who are EBV antibody positive shed the virus in their oral secretions (6-8). Reactivation of the latent viral carrier state, as evidenced by increased rates of virus shedding, is enhanced by immunosuppression, pregnancy, malnutrition, or disease (8,9). Chronic EBV infections, whether latent or active, are rarely associated with disease. However, EBV has been implicated at least as a contributing factor in the etiology of asopharyngeal carcinoma, Burkitt’s lymphoma, and lymphomas in immunodeficient patients (4,8).
The Paul-Bunnell-Davidsohn test for heterophile antibody is highly specific for IM (10). However, 10-15% of adults and higher percentages of children and infants with primary EBV infections do not develop heterophile antibodies (11). EBV-specific serotogical tests are needed to differentiate primary EBV infections that are heterophile negative from mononucleosis-like illnesses caused by other agents such as cytomegalovirus, adenovirus, and Toxoplasma gondii (4). Antibody tilers to specific EBV antigens correlate with different stages of JM (4, 10-12). Both IgM and IgG antibodies to the viral capsid antigen (VGA) peak 3 to 4 weeks after primary EBV infection. IgM anti-VCA decline rapidly and is usually undetectable after 12 weeks. IgG anti- VCA liters decline slowly after peaking but last indefinitely. Antibodies to EBV nuclear antigen (EBNA) develop from 1 month to 6 months after infection and, like anti-VCA, persist indefinitely (11,12). Antibodies to EBNA indicate that the infection was not recent (11).
EBV early antigens (EA) consist of two components; diffuse (D), and restricted (R). The terms D and R reflect the different patterns of immunofluorescence staining exhibited by the two components (13,14). Antibodies to EA appear transiently for up to three months during the acute phase of IM in 85% of patients (15,16). The antibody response to EA in IM patients is usually to the D component, whereas silent seroconversion to EBV in children produces antibodies to the R component (5,11). A definitive diagnosis of primary EBV infection can be made with 95% of acute phase sera based on the detection of antibodies to VCA, EBNA, andEA(12).
High levels of anti-VCA together with anti-EBNA and anti-EA-R are associated with reactivation of the latent viral carrier state (16,17). High levels of IgG anti-VCA are found in sera of patients with immunodeficiencies (6,18), recurrent parotitis (19), multiple sclerosis (20), and nasopharyngeal carcinoma (21); as well as immunosuppressed patients (8, 22), pregnant women (23), and persons of advanced age (17).
Screening for the presence of antibodies to VCA and related antigens of EBV can provide important information for the diagnosis of EBV infection. Indirect immunofluorescence has been the serologic method most commonly used to detect antibodies to EBV antigens (11). However, the ELISA procedure, first described by Engvall and Penman (24,25), may be a sensitive and reliable method for detection of antibodies to EBV antigens (26,27). The ELISA procedure allows an objective determination of antibody status to be made on a single dilution of the test specimen and is suitable for screening large numbers of patient samples.
- Materials Provided – conjugate, plate, positive control, negative control, calibrator, sample diluent, stop solution, TMB, wash buffer concentrate (10X), (red cap) containing 1 M H2SO4, 0.7M HCI. Ready to use.
- Storage – The unopened kit can be stored between 2° and 8°C.
For more information about the Epstein Barr Virus VCA IgM, 96 wells and other infectious disease kits, visit our online store. For more information about our product line, dial 631-589-1118 or send an email to firstname.lastname@example.org.